PMID- 11399702
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20190514
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 119
IP  - 6
DP  - 2001 Jun
TI  - Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle 
      strength in patients with heart failure.
PG  - 1755-60
AB  - STUDY OBJECTIVES: Respiratory muscle strength has been shown to be reduced in 
      patients with chronic heart failure. The purpose of this prospective study was to 
      determine whether long-term therapy with the angiotensin-converting enzyme (ACE) 
      inhibitor perindopril improves respiratory muscle strength in patients with 
      chronic heart failure. PATIENTS AND METHODS: Eighteen patients with stable 
      chronic heart failure were administered perindopril, 4 mg/d, in addition to their 
      standard therapy for a period of 6 months. Fourteen patients completed the study. 
      Maximum inspiratory pressure (PImax) and maximum expiratory pressure (PEmax) 
      expressed in percentage of predicted values, left ventricular ejection fraction 
      (LVEF) determined by means of two-dimensional echocardiography, and pulmonary 
      volumes were obtained before and after therapy. MEASUREMENTS AND RESULTS: As 
      compared to baseline, there was a significant increase in both PImax and PEmax 
      after therapy (57 +/- 27% predicted vs 78 +/- 36% predicted and 62 +/- 20% 
      predicted vs 73 +/- 15% predicted, respectively; each p < 0.05). LVEF increased 
      (34 +/- 5% vs 41 +/- 10%; p < 0.05); functional class improved by > or = 1 New 
      York Heart Association (NYHA) class in five patients. There were no changes in 
      pulmonary volumes. No correlation was found between changes in PImax and PEmax 
      and changes in either LVEF or NYHA functional class. CONCLUSIONS: In patients 
      with chronic heart failure, long-term therapy with the ACE inhibitor perindopril 
      improved respiratory muscle strength, as indicated by significant increases in 
      PImax and PEmax.
FAU - Coirault, C
AU  - Coirault C
AD  - U451 INSERM, Laboratoire d'Optique Appliquee-ENSTA-Ecole Polytechnique, 
      Palaiseau, France. coirault@enstay.ensta.fr
FAU - Hagege, A
AU  - Hagege A
FAU - Chemla, D
AU  - Chemla D
FAU - Fratacci, M D
AU  - Fratacci MD
FAU - Guerot, C
AU  - Guerot C
FAU - Lecarpentier, Y
AU  - Lecarpentier Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - Y5GMK36KGY (Perindopril)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use
MH  - Chronic Disease
MH  - Echocardiography
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Perindopril/administration & dosage/*therapeutic use
MH  - Prospective Studies
MH  - Respiratory Muscles/*drug effects/physiology
MH  - Stroke Volume/drug effects
EDAT- 2001/06/16 10:00
MHDA- 2001/07/13 10:01
CRDT- 2001/06/16 10:00
PHST- 2001/06/16 10:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/06/16 10:00 [entrez]
AID - S0012-3692(15)52324-6 [pii]
AID - 10.1378/chest.119.6.1755 [doi]
PST - ppublish
SO  - Chest. 2001 Jun;119(6):1755-60. doi: 10.1378/chest.119.6.1755.